Key TakeawaysThe global vaccines market reached USD 87.57 billion in 2024 and is projected to grow to USD 206.78 billion by ...

The FDA has given a fast-track designation to a gonorrhoea vaccine in development at GSK that could help turn the tide of the sexually-transmitted infection, which is on the rise ...

Brown & Brown, Cintas Corporation, Haleon, Linde, Raia Drogasil and Veeva Systems are making access to health and hygiene more equitable. EDINBURGH, ...

The United States has approved a twice-a-year jab that almost entirely protects against HIV in what’s being hailed as a ...

Gilead Sciences said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a convenient new way to ward off infection in a wide range of people.

BP's rival, Shell, has expressed interest in a takeover. That would be the least-worst option for Britain’s beleaguered oil ...

Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent effectiveness in trials. Here's how it works, and what it costs.

GSK Licenses Shigella Vaccine altSonflex1-2-3 to Bharat Biotech: Strategic licensing agreement advances late-stage development and expands potential vaccine access in low- and middle-income countries.

This new award strengthens CCfV, Dalhousie, and GSK's shared commitment to driving impactful health research that benefits all communities, particularly focusing on addressing health equity gaps.

Bharat Biotech joins GSK to develop a Shigella vaccine to fight shigellosis in children, with Phase 3 trials underway and focus on low-income countries.